Trial Profile
A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2019
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Head and neck cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 04 Dec 2018 Results assessing safety and pharmacokinetics of rigosertib in patients with myelodysplastic syndromes, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 29 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 30 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov